Editorial Board ::: Current Drug Discovery Technologies

ISSN: 1875-6220 (Online)
ISSN: 1570-1638 (Print)


Volume 13, 4 Issues, 2016


Download PDF Flyer




Current Drug Discovery Technologies

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Vladimir P. Torchilin
Department of Pharmaceutical Science Center
for Pharmaceutical Biotechnology and Nanomedicine
Northeastern University
Boston, MA 02115
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Editorial Board

Editor-in-Chief:

Vladimir P. Torchilin (Biography
Vladimir P. Torchilin

Vladimir P. Torchilin, Ph.D., D.Sc. is a University Distinguished Professor of Pharmaceutical Sciences and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. His interests include drug delivery and targeting, nanomedicine, multifunctional and stimuli-sensitive pharmaceutical nanocarriers, biomedical polymers, experimental cancer therapy. He has published more than 400 original papers, more than 150 reviews and book chapters, wrote and edited 12 books, and holds more than 40 patents. Google Scholar shows more than 44,000 citations of his papers with H-index of 96. He is Editor-in-Chief of Current Drug Discovery Technologies, Drug Delivery, and OpenNano, Co-Editor of Current Pharmaceutical Biotechnology and on the Editorial Boards of many other journals. He received more than $30 M from the governmental and industrial sources in research funding. He has multiple honors and awards and in 2011, Times Higher Education ranked him number 2 among top world scientists in pharmacology for the period of 2000-2010.

)

Department of Pharmaceutical Science Center
for Pharmaceutical Biotechnology and Nanomedicine
Northeastern University
Boston, MA 02115
USA



Regional Editor(s):

Grzegorz Bazylak
Nicolaus Copernicus University
Bydgoszcz
Poland

Eduardo A. Castro
INIFTA, Theoretical Chemistry Division
La Plata, Buenos Aires
Argentina

Detlev Boison (Biography
Detlev Boison

Having a passion for translational research I seek to translate fundamental mechanisms of biochemistry and energy homeostasis into novel therapeutic approaches for the treatment of neurological and psychiatric conditions. A major research effort is the development of adenosine augmentation therapies for the treatment of epilepsy. I graduated at the University of Cologne, Germany, in 1994 with a PhD in Biochemistry. In 1995 I started my independent research career at the University and Federal Institute of Technology in Zurich where I received the venia legendi in Cellular Pharmacology in 2005 for my work on cell-based adenosine augmentation therapies for epilepsy. That same year I joined Legacy Health in Portland, Oregon, where I am currently Chair and Director of the Robert Stone Dow Neurobiology Laboratories and Director of Basic and Translational Research of the Legacy Research Institute. In addition, I hold faculty appointments at Oregon Health and Science University and at Washington State University.

)

RS Dow Neurobiology Laboratories
Portland, OR
USA

Yiyun Cheng
East China Normal University
Shanghai
China

Martin Braddock
AstraZeneca Research and Development
Leicestershire
UK


Section Editor(s):

(Environmental Endocrinology)
M. Ishido
National Institute for Environmental Studies
Tsukuba
Japan


Editorial Board Members:

Mohammad Abdollahi (Biography
Mohammad Abdollahi

Mohammad Abdollahi (MA) holding Doctor of Pharmacy and PhD in Pharmacology and Toxicology is an academic and expert in the field of Mechanistic and Clinical Toxicopharmacology. He is currently Professor at the Tehran University of Medical Sciences and chairs the Pharmaceutical Sciences Research Center. He has contributed in authoring more than 700 papers in esteemed journals and authoring 50 book chapters and editing 12 books from prominent publishers. He has been listed among top scientists of ESI/ISI and OIC Member States. According to GS, current H-index, total citations, and i10 index of MA are 68, >18500, and 373, respectively. He is the Editor-in-Chief (EiC) of DARU Journal of Pharmaceutical Sciences published by BMC Springer Nature. He has also served on the editorial board of many journals and is a Council Member of the Committee on Publication Ethics (COPE).

)

Tehran University of Medical Sciences
Tehran
Iran

A. Ahad (Biography
A. Ahad

Dr. Abdul Ahad is an Assistant Professor at Department of Pharmaceutics, College of Pharmacy, King Saud University Riyadh, Saudi Arabia. Dr. Ahad did his Master and Doctorate in Pharmaceutical Sciences from Department of Pharmaceutics, Jamia Hamdard, New Delhi, India. He has published various high quality research and review articles in several peer-reviewed journals of international repute. He is on Editorial Board of several Pharmaceutical journals and reviewer of many peer-reviewed journals. His current interest lies in Nanotechnology products for dermal/transdermal drug delivery and lipid based formulations.

)

King Saud University
Riyadh
Saudi Arabia

M.B. Brown
University of Hertfordshire
Herts
UK

J.P.F. Chin-Dusting
Baker Heart Research Institute
Melbourne
Australia

J.-V. De Julian Ortiz
Polytechnic University of Valencia
Valencia
Spain

X. Deng (Biography
X. Deng

Dr. Deng is a faculty member engaged in cancer research and has held the appointment of associate professor in the Department of Radiation Oncology at Emory University School of Medicine. Dr. Deng completed his postdoctoral training at the University of Texas Medical Branch. Major research interests are to develop novel small molecule anti-cancer agents and new therapeutic strategies for cancer therapy by targeting apoptosis and DNA repair signaling pathways. He has published more than 87 scientific publications and is a named inventor of 3 issued U.S patents.

)

Emory University School of Medicine
Atlanta, GA
USA

E. Estrada (Biography
E. Estrada

Professor Estrada is the 1964 Chair of Mathematics and Chair in Complexity Sciences at the University of Strathclyde, Glasgow, U.K. He is also the President of the International Academy of Mathematical Chemistry and a Member of the Academia Europaea. He obtained his PhD in Mathematical Chemistry at the UCLV in Cuba. His research interests are on the mathematical analysis of complex networked systems as well as in mathematical chemistry and molecular design. He is well-known for the development of the TOPS_MODE approach to drug design, protein structure analysis and for the analysis of biological networks.

)

University of Strathclyde
Scotland
UK

D.R. Flower
Aston University
Birmingham
UK

J.C. Glorioso
University of Pittsburgh
Pittsburgh, PA
USA

C.P. Hart (Biography
C.P. Hart

Charles Hart joined Threshold Pharmaceuticals in 2004 and is currently Senior Vice President for Discovery Research. He is responsible for both in vitro and in vivo preclinical translational studies. Prior to joining Threshold he held positions at Galileo Pharmaceuticals, Signature Bioscience, and the Affymax Research Institute. Charles received his A.B. in cell biology from the University of California at Berkeley in 1977, an M.S. in developmental biology from Stanford University in 1980, a Ph.D. in molecular biology and genetics from Yale University in 1987, and completed a postdoctoral fellowship at the University of Strasbourg, France.

)

Threshold Pharmaceuticals
Redwood City, CA
USA

K. Houk
University of California
Los Angeles, CA
USA

K. Islam
Arpida Ltd
Muenchenstein
Switzerland

J. Kardos (Biography
J. Kardos

Julianna Kardos Ph.D. (1973), D.Sc. (1991) studied chemistry at the Eötvös Loránd University, Budapest, Hungary in 1964-1969. She was associate professor in pharmacology (1986-1987: Georgetown University, Washington DC, USA), research specialist in biochemistry (1988, 1989: University of Missouri-Columbia, St.Louis, MO, USA) and research specialist in pharmacy (1993, 1995: Royal Danish School of Pharmacy), head of department (1995-2011: Chemical Research Center, Hungarian Academy of Sciences, HAS) and director of the Institute of Molecular Pharmacology (2012-2013). She is currently professor emeritus at the Research Centre for Natural Sciences, HAS, Budapest. She is the recipient of the Award of HAS, Budapest, Hungary (2006).

)

Hungarian Academy of Sciences
Budapest
Hungary

S. Klussmann
Noxxon Pharma AG
Berlin
Germany

M.S. Lajiness
Eli Lilly and Company
Indianapolis, IN
USA

C. Lipinski
Pfizer Global R&D
Waterford, CT
USA

C.R. Martin
University of Florida
Gainesville, FL
USA

L.M. Mayr (Biography
L.M. Mayr

Lorenz is working as Vice President, Reagents & Assay Development with global responsibility for generation of biological reagents and assay development activities at AstraZeneca. This includes generation of proteins and cell lines for hit finding, hit-to-lead and lead optimisation activities including structure & biophysics activities across all therapeutic research areas, the generation of tool antibodies, transgenic animals, stem cells and primary cells as tools for target validation studies and lead optimisation programmes. His department in the UK and Sweden is responsible for assay development activities for biochemical, cell-based and phenotypic assays for all therapeutic areas at AstraZeneca. Current research interests of the RAD Department are in the areas of precise-genome editing (PGE), transcriptomics, secretomics, high-content biology, novel antibody scaffolds and affinity reagents, next-generation sequencing (NGS) and the use of these technologies in complex 3D cellular models/organoids for target validation and lead optimisation.

)

AstraZeneca Pharmaceuticals Ltd.
Cheshire
USA

S.M. Moghimi
School of Medicine, Pharmacy and Health
Durham University
Queen's Campus
UK

D.J. Muller
University of Technology Dresden
Dresden
Germany

T. Ochiya (Biography
T. Ochiya

Dr. Takahiro Ochiya is a Chief of Division of Molecular and Cellular Medicine at the National Cancer Center Research Institute, Tokyo. Dr. Ochiya carried a councilor of Japanese Cancer Association. After he got Ph.D. in 1988 in Osaka University and then went to do a post-doc at La Jolla Cancer Research (SF Burnham Institute for Medical Research), CA, USA. Dr. Ochiya’s lab focuses the development of novel animal models, methods, and strategies to study cancer development and metastasis. Especially, current focuses are siRNA- and microRNA-based therapy and exosome-mediated tumor metastasis. Dr. Ochiya has authored more than 280 peer-reviewed publications including 40 review articles, holds 26 Japan and 8 U.S. & Europe patents, and contributed to several books on stem cells, Extracellular vesicles, and RNAi medicine.

)

National Cancer Center Research Institute
Tokyo
Japan

K.H. Pearce
GlaxoSmithKline
GlaxoSmithKline, NC
USA

Y.G. Pommier
National Institutes of Health
Bethesda, MD
USA

R. Roy
Universite du Quebec a Montreal
Montreal, QC
USA

J. Schlessinger
Yale University
Yale University, CT
USA

P.J. Sinko
Rutgers University
Piscataway, NJ
USA

G. Subramanian
Sanofi-aventis
New Jersey, NJ
USA

Y. Takei
Nagoya University
Nagoya
Japan

F. Torrens (Biography
F. Torrens

Dr. Torrens obtained a doctorate (Ph.D.) in Physical Chemistry from the Universitat de València, Spain. Currently Dr. Torrens is Lecturer in Physical Chemistry in the Universitat de València. His scientific accomplishments include the first implementation in a computer at the Universitat de València of a program for the elucidation of crystallographic structures and the construction of the first computational-chemistry program adapted to a vector-facility supercomputer in a Spanish university. He has published 2 books, 370 articles and 1672 presentations. He has been Advisor of 4 Ph.D. and 1 M.Sc.

)

University of Valencia
Valencia
Spain

J. Vaidyanathan
University of Medicine and Dentistry of NJ
Newark, NJ
USA

L.C. Wienkers
Amgen Inc
Seattle, WA
USA

A.K. Yudin
University of Toronto
Toronto, Ontario
Canada

J. Zhou (Biography
J. Zhou

Dr. Zhou is a tenured Professor in the Chemical Biology Program at University of Texas Medical Branch (UTMB). He was educated and trained from Nankai University, University of Virginia, and Georgetown University Medical Center, respectively. He has over 20 years of research experience in drug discovery and development including 7 years of industrial experience in pharmaceuticals. His research interest is developing novel small molecules as valuable chemical probes and potential therapeutics for central nervous system disorders, cancer/inflammation, and infectious diseases. He has published more than 100 peer-reviewed journal papers, 6 book chapters, and 15 patents.

)

University of Texas
Galveston, TX
USA

B.B. Aggarwal
University of Texas, MD Anderson Cancer Center
Houston, TX
USA

A.M. Aronov
Vertex Pharmaceuticals, Inc
Cambridge, MA
USA

R. Bucala
Yale University School of Medicine
New Haven, CT
USA

R. Cortesi (Biography
R. Cortesi

Dr. Rita Cortesi obtained her doctorate (Ph.D.) in Pharmaceutical Sciences from the University of Ferrara, Italy. She attended a HMC Post-doc fellowship at Pharmaceutical Sciences Department of Nottingham University (U.K.).

Currently Dr. Cortesi is an Associate Professor at the Department of Life Sciences and Biotechnology of Ferrara University. She has published more than 120 scientific publications considering papers on international journal, book’s chapters and patents. Dr. Cortesi currently belongs to the Editorial Board of this journal (Current Drug Discovery Technologies, CDDT), published by Bentham Science Publishers.

)

Ferrara University
Ferrara
Italy

M.M. De Villiers (Biography
M.M. De Villiers

Melgardt de Villiers is Professor and Associate Dean at the School of Pharmacy - University of Wisconsin. His research focuses on developing innovative nano and micro particulate drug delivery systems. He is the author of 150 peer reviewed publications and book chapters and has presented his research at meetings more than 200 times. He has supervised 17 PhD and 21 MS students. In 2005 he was the Outstanding Professor in the College of Health Sciences at the University of Louisiana at Monroe and in 2012 he was elected as a fellow of the American Association of Pharmaceutical Scientists (AAPS).

)

University of Wisconsin
Madison, WI
USA

I. Doytchinova
Medical University of Sofia
Sofia
Bulgaria

Y. Fang (Biography
Y. Fang

Dr. Ye Fang is the Research Director/Fellow of the Biochemical Technologies in the Science & Technology Division at Corning Incorporated in New York (NY, USA). He received his BSc in Chemistry from the Hubei University, MSc in Physical Chemistry from the Wuhan University, and Ph.D in Physical Chemistry from the Institute of Chemistry, Chinese Academy of Sciences, all in China. Following postdoctoral research at the University of Vermont from 1995 to 1996 and at the Johns Hopkins University School of Medicine from 1996 to 2000, he joined Corning Incorporated. Over the last 24 years, he has focused his scientific interests on the biophysical aspects of bio-macromolecules and cells, as well as the development of innovative biotechnologies for cell biology, drug discovery, and bioprocess. He has published 2 books, 24 book chapters, and more than 120 journal articles. He holds 28 US granted patents and 70 patent applications. His current research interests are Biosensors, Biophysics, Bioprocess, Chemical Biology, Drug Discovery, and Pharmacology.

)

Corning Inc
Corning, NY
USA

A. Fura
Bristol-Myers Squibb R&D
Princeton, NJ
USA

B. Gold
National Cancer Institute
Frederick, MD
USA

A. Hillisch
Bayer HealthCare AG
Wuppertal
Germany

J. Huard
Department of Orthopaedic Surgery
University of Texas Health Science Center at Houston
Houston
United States

S. Jana (Biography
S. Jana

Dr. Snehasis Jana has more than 15 years of new drug discovery and development research experience in various Indian pharmaceutical industries. He holds a basic degree in Pharmaceutical Sciences, a PhD in Molecular mechanisms of Drug Resistance Mechanisms (Molecular Pharmacology & Biotechnology) from Dept. of Biochemical Engg. & Biotechnology, IIT-Delhi, India and has extensive drug discovery & developmental research experience in various therapeutic targets at Ranbaxy, BMS-Biocon Research Center, Sai Life Science & Laila Nutraceuticals. He is an expert for establishing strategic directions for preclinical/clinical nutra/pharmaceuticals discovery research focused on Anticancer, Chemopreventive agents, Probiotics/prebiotics, hepatoprotective, anti-infective, anti-inflammatory, arthritis, Cardiovascular, anti-aging, obesity, diabetes, Cognition & Memory, and Overall health etc. Dr. Jana's publication record exceeds 45 research articles and reviews.

)

Trivedi Science Research Laboratory
Madhya Pradesh
India

K. Kariko
University of Pennsylvania School of Medicine
Philadelphia, PA
USA

M. Komada
Komada
Yokohama
Japan

J.M. Lehn
Nobel Laureate Institut Le Bel
Cedex
France

S.A. Lipton
University of California
La Jolla, CA
USA

L.C. Mattheakis (Biography
L.C. Mattheakis

Dr. Mattheakis is currently Vice President of Biology at Protagonist Therapeutics. His nearly 25 years of experience in biotech R&D includes developing novel technologies for drug screening and leading preclinical programs in oncology and immune disorders. He is the author of numerous publications and inventor on key patents. Dr. Mattheakis received a Ph.D. in Biochemistry from the University of Wisconsin-Madison, and trained as a post-doctoral research fellow in the Department of Microbiology and Molecular Genetics at Harvard Medical School. He is a member of Faculty of 1000 in Chemical Biology, and serves as an editor for the Journal of Biomolecular Screening (SLAS Discovery).

)

Protagonist Therapeutics
Menlo Park, CA
USA

L.K. Minor
Johnson & Johnson Pharmaceutical R&D
Spring House, PA
USA

M. Moloney
University of Oxford
Oxford
UK

Kohzo Nakayama
Shinshu University
Nagano
Japan

H. Onishi
Hoshi University
Tokyo
Japan

R.T. Peterson
Massachusetts General Hospital
Charlestown, MA
USA

I.N. Rich
HemoGenix, Inc
Colorado Springs, CO
USA

M. Ruvo
University of Naples
Napoli
Italy

V. Shanmugasundaram
Pfizer PharmaTherapeutics Research & Development
Groton, CT
USA

C.P. Sosa
University of Minnesota
Minneapolis, MN
USA

K. Sugahara (Biography
K. Sugahara

Dr. Sugahara obtained master’s degree (MS) and Ph.D. in Biological Chemistry from the Faculty of Pharmaceutical Sciences, Kyoto University, Japan. He awarded Honorary Doctor of Medicine from Uppsala University, Sweden in 2002, and Human Frontier Science Award (Strasbourg) in 2000 and 2010. He has published over 220 peer reviewed original scientific publications and over 20 review articles, and specializes in glycobiology of sulfated polysaccharides and extracellular matrix proteins. Currently he is Emeritus Professor, Hokkaido University, Sapporo, Japan, and Research Fellow at Department of Pathobiohemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.

)

Hokkaido University Graduate School of Life Science
Hokkaido
Japan

I.V. Tetko (Biography
I.V. Tetko

Dr. Igor V. Tetko obtained his MSc degree (with honor) from the Moscow Institute of Physics and Technology (USSR), PhD from the Ukrainian Academy of Sciences and Habilitation in Chemoinformatics from the University of Strasbourg. He is Chemoinformatics group leader at the Helmholtz Zentrum München, Germany where he coordinates Horizon2020 Marie Skłodowska-Curie Innovative Training Network (ITN) “Big Data in Chemistry”. Dr. Tetko is also CEO of BIGCHEM GmbH, which develops and licenses software technologies for big data analysis in chemistry and life sciences. Dr. Tetko is on the list of The Most Cited Researchers in Computer Sci. & Eng.

)

Institute for Bioinformatics
Neuherberg
Germany

G. Trainor
Bristol-Myers Squibb Pharmaceutical
Delaware, NJ
USA

M.A. Walker
Bristol-Myers Squibb R&D
Wallingford, CT
USA

M.S. Wolfe
Harvard Medical School
Boston, MA
USA

Y. Zhang
Johns Hopkins University
Baltimore, MD
USA

A.K. Agrawal
ImmuPharma plc
London
UK

C.R. Bramham
University of Bergen
Bergen
Norway

K.K. Chan
The Ohio State University
Ohio, OH
USA

M. Cristofanilli
The University of Texas
Houston, TX
USA

A. Degterev (Biography
A. Degterev

Dr. Degterev is an Associate Professor at the Department of Developmental, Molecular and Chemical Biology at Tufts University. His work focuses on the analysis of the mechanisms and development of the small molecule modulators of cell death processes that contribute to human pathologies. Dr. Degterev pursues multidisciplinary studies combining cell and chemical biology, and animal pharmacology. Dr. Alexei Degterev earned M.S. in Chemistry from Moscow State University, Russia and Ph.D. in Biochemistry from Boston University School of Medicine, MA. Upon graduation, he joined the laboratory of Dr. Junying Yuan in the Department of Biology of Harvard Medical School as a post-doctoral fellow and, subsequently, as Instructor in Cell Biology. Since November 2005, Dr. Degterev is an Assistant Professor of Biochemistry at Tufts University. Dr. Degterev is a recipient of the Mentored Career Development Award from the National Institute on Aging, Alzheimer’s Research Pilot Award from the American Health Assistance Foundation and Smith Family Award for Excellence in Biomedical Research from the Massachusetts Medical Foundation. Dr. Degterev is the author of multiple patents and more than 60 scientific publications.

)

Tufts University School of Medicine
Boston, MA
USA

T.L. Dunckley
Translational Genomics Research Institute
Phoenix, AZ
USA

M. Feher
D. E. Shaw Research
New York, NY
USA

Z.-G. Gao
National Institutes of Health
Bethesda, MD
USA

J.A. Grosso
Bristol-Myers Squibb R&D
Princeton, NJ
USA

A.G. Horti (Biography
A.G. Horti

Andrew G. Horti an Associate Professor in the Department of Radiology, Division of Nuclear Medicine and Molecular Imaging at the Johns Hopkins University School of Medicine. He has over 25 years of experience in medicinal radiochemistry. He holds a PhD in organic synthesis and physical chemistry from Leningrad Institute of Technology. Notably, Dr. Horti has authored more than 100 manuscripts, patents, and book chapters. His current research projects focus on the discovery of short-lived radiotracers, in particular, radioligands for PET imaging of cerebral receptors and enzymes.

)

Johns Hopkins University
Baltimore, MD
USA

A.C. Hunter
University of Manchester
Manchester
UK

J.W. Janetka
Washington University School of Medicine
Saint Louis, MO
USA

T. Kenakin
University of North Carolina School of Medicine
Chapel Hill, NC
USA

W.A. Korfmacher
Schering-Plough Research Institute
Kenilworth, NJ
USA

J.-P. Leonetti
Centre de Pharmacologie et Biotechnologie pour la Sante
Montpeillier
France

E. Lolis
Yale University
New Haven, CT
USA

N. Maulik
University of Connecticut School of Medicine
Farmington, CT
USA

L. Mitscher
University of Kansas
Lawrence, KS
USA

K. Mueller
Hoffman-La Roche Ltd
Basel
Switzerland

J.P. O'Bryan
University of Illinois College of Medicine
Chicago, IL
USA

E. Paleolog
Imperial College
London
UK

G. Poda
Ontario Institute for Cancer Research
Toronto, ON
Canada

D.D. Root (Biography
D.D. Root

Dr. Root earned a PhD from the Molecular Biology Institute at the University of California, Los Angeles. Dr. Root currently designs and synthesizes small molecule modulators of muscle force generation based on structural and functional studies of protein interactions using spectroscopic and single molecule assays, several of which were developed in his laboratory. In addition, Dr. Root has directed courses in Biochemistry at the University of North Texas for 20 years.

)

University of North Texas
Denton, TX
USA

D.K. Sarker
University of Brighton
Brighton
UK

K.B. Sharpless
The Scripps Research Institute (TSRI)
La Jolla, CA
USA

L. Stewart
deCODE biostructures Inc
Bainbridge Island, WA
USA

D.R. Taft
Long Island University
Brooklyn, NY
USA

A.A. Toropov (Biography
A.A. Toropov

Andrey A. Toropov (PhD) has been working in Istituto di Ricerche Farmacologiche Mario Milano, Italy with Dr. Benfenati’s research group. The optimal (flexible) descriptors are his main scientific interest. He is developer of recent version of the optimal descriptors named as collectors of eclectic data for a QSPR/QSAR predictions. This paradigm is especially appropriate for the cases of complex molecular systems such as nanomaterials and proteins. He had done contribution for the development of the CORAL freeware (http://www.insilico.eu/coral). He had published of about 220 papers in international journals on the QSPR/QSAR analysis: physicochemical properties, toxicity, cancirogenicity, anticancer agents, anti-HIV-1 agents, QSPR/QSAR analysis for nanomaterials. He was participant of the following EC projects: DEMETRA, CHEMPREDICT, PROSIL, ORCHESTRA, ANTARES, OSIRIS, NanoBRIDGES, PreNanoTox, NanoPUZZLES etc. He is participant in work of Editorial Boards of scientific journals (as a reviewer). He has been visiting scientist in Jackson State University (USA, Mississippi), in 2006-2007.

)

IRCCS-Istituto di Ricerche Farmacologiche Mario Negri
Milano
Italy

S.M. Turner
KineMed, Inc
Emeryville, CA
USA

P.A. Wender (Biography
P.A. Wender

Paul Wender received his PhD from Yale University, was an NIH Fellow at Columbia University, served on the faculty at Harvard University and is currently the Bergstrom Professor of Chemistry and Professor of Chemical and Systems Biology at Stanford University. He serves on several internal and external advisory board and has founded various companies based on his research. His work is described in >300 publications and >20 issued or pending patents. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, the American Association of Arts and Sciences, and the Royal Spanish Academy of Sciences. His work has been recognized with numerous awards, including more recently the 2015 Stanford Office of Technology Licensing Innovator Award, 2015 Israel Chemical Society Cohen Award for Excellence in Medicinal Chemistry, 2015 ACS Cope Award, and the 2016 Research Award of the German Bioactives and Biotechnology Leibniz Alliance.

)

Stanford University
Stanford, CA
USA

S. Yamagishi (Biography
S. Yamagishi

Sho-ichi Yamagishi is a Professor and Chairman, Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Japan.

He has graduated from Kanazawa University School of Medicine, Japan and became a medical doctor in 1989. He has received a PhD from Kanazawa University, Japan in 1993. He received Basic Science Award "Angiogenesis Stem Cell Award" from American Heart Association in 2003 and "Distinguished Investigator Award from Japan Diabetes Society in 2005. He is serving as an editorial board member of 20 reputed journals and publishes more than 550 research papers, including Nature, JCI, and Diabetes, etc. His research fields are Diabetes, Cardiology and Gerontology.

)

Kurume University School of Medicine
Kurume
Japan

X.F.S. Zheng
UMDNJ-Robert Wood Johnson Medical School
Piscataway, NJ
USA


Advertisement

Related Journals




Related eBooks


Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science